ASSESSMENT OF SULFONYLUREA ADHERENCE AND METABOLIC CONTROL

被引:53
作者
MASON, BJ
MATSUYAMA, JR
JUE, SG
机构
[1] Idaho State University College of Pharmacy, Veteran Affairs Mcdical Center, Boise, Idaho
[2] Idaho State University College of Pharmacy, Saint Alphonsus Medical Center, Boise, Idaho
关键词
D O I
10.1177/014572179502100109
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study was designed to compare sulfonylurea adherence assessment by providers, patients' self-report, pill counts, and a medication event monitoring system (MEMS-3(R)) device, and correlate the estimates of metabolic control by provider, patient, and laboratory. Forty-seven outpatient veterans with fair to poor metabolic control of non-insulin-dependent diabetes mellitus were enrolled and received monthly refills of sulfonylurea in vials with a cap containing an electronic medication monitoring microprocessor. Pill counts and fasting plasma glucoses were measured monthly, and glycohemoglobin and a 24-hour diet recall were obtained at 0 and 60 days. Investigators then asked providers and patients to assess adherence and metabolic control. Forty-seven percent were nonadherent to medication using MEMS-3(R), 29% using pill counts, 29% using provider assessment, and 31% using self-report. Thirty-one percent of providers and 53% of patients assessed metabolic control differently than laboratory values. Assessment of medication adherence by provider, patient, and pill counts did not explain metabolic control as closely as assessment by MEMS-3(R).
引用
收藏
页码:52 / 57
页数:6
相关论文
共 16 条
[1]  
Berf J.S., Medication compliance: a healthcare problem, Ann Pharmacother, 27, pp. 3-19, (1993)
[2]  
Emerging issues in pharmaceutical cost containment, pp. 1-16, (1992)
[3]  
Leichter S.B., Archer R., Analyzing “noncompliance”, Practical Diabetol, 10, 6, pp. 1-6, (1991)
[4]  
Pendleton L., House W.C., Parker L.E., Physicians' and patients' views of problems of compliance with diabetes regimens, Public Health Rep, 102, pp. 21-26, (1987)
[5]  
Sackett D.L., Snow J.C., The magnitudes of compliance and noncompliance, pp. 11-22, (1979)
[6]  
Rudd P., Byyny R.L., Zackary V., Pill counts measures of compliance in a drug trial: variability and suitability, Am J Hypertens, 1, pp. 309-312, (1988)
[7]  
Pullar T., Kumar S., Tindall H., Time to stop counting the tablets, Clin Pharmacol Ther, 46, pp. 163-168, (1989)
[8]  
Rudd P., Byyny R.L., Zackary V., The natural history of medication compliance in a drug trial: limitations of pill counts, Clin Pharmacol Ther, 46, pp. 169-176, (1989)
[9]  
Rifkin H., The physician's guide to non-insulin-dependent diabetes (type II) diagnosis and treatment, (1988)
[10]  
Matsuyama J., Mason B., Jue S., Pharmacists' interventions using an electronic medication-event monitoring device's adherence data versus pill counts, Ann Pharmacother, 27, pp. 851-855, (1993)